Leishmaniasis Research and Treatment Center

University of Gondar

Leishmaniasis

Visceral Leishmaniasis

Hyperthermia

Growth Disorders

Recurrence

Fever

Cutaneous Leishmaniasis

LXE408

Institute of Tropical Medicine, Belgium

University of Washington

Drugs for Neglected Diseases

condition

allSponsorName

Novartis

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and \<45 years) patients with confirmed primary visceral leishmaniasis in Ethiopia.

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

University of Gondar | Leishmaniasis Research and Treatment Center

Site insights

Work at this site?

Active trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Trial sponsors